Related Experiment Videos
Humoral immune response to cruzipain and cardiac dysfunction in chronic Chagas disease
V G Duschak1, A Riarte, E L Segura
1Instituto de Investigaciones Biotecnólogicas, Universidad Nacional de General San Martín, INTI. Av. Gral. Paz entre Albarellos y Constituyentes (Edificio 24) Casilla de Correo 30 (1650), San Martín, Buenos Aires, Argentina.
Insights
The study investigated the immune response to cruzipain in Chagas disease patients (CDP). Higher anti-cruzipain antibody levels correlated with severe heart conditions in CDP, suggesting a link between immune response and disease severity.
Area of Science:
- Immunology
- Parasitology
- Cardiology
Background:
- Chagas disease, caused by Trypanosoma cruzi, affects millions globally, often leading to chronic cardiac complications.
- Cruzipain, a major T. cruzi antigen, plays a role in parasite invasion and survival.
- The humoral immune response to cruzipain in Chagas disease patients (CDP) and its association with cardiac dysfunction remain incompletely understood.
Purpose of the Study:
- To investigate the humoral immune response to specific epitopes on cruzipain in CDP.
- To determine if this immune response correlates with the severity of cardiac dysfunction in CDP.
Main Methods:
- Evaluated antibody responses to cruzipain epitopes in 31 CDP with varying cardiac dysfunction.
- Utilized monoclonal antibodies (MoAbs) reactive with T. cruzi epitopes recognized or not recognized by CDP sera.
- Assessed the inhibition of MoAb binding to cruzipain by CDP sera and measured anti-cruzipain antibody titers.
Main Results:
- Sera from severe cardiopathy patients significantly inhibited the reactivity of a specific anti-cruzipain epitope (5A9B11), unlike sera from mild disease patients.
- CDP sera did not block recognition of another epitope (1A10C11) on cruzipain.
- A strong correlation was observed between high anti-cruzipain antibody titers (>1/800) and severe cardiac dysfunction, with 70% of severe cases exhibiting these titers.
Conclusions:
- The humoral immune response targeting specific epitopes on cruzipain is associated with the severity of chronic Chagas disease cardiac pathology.
- These findings suggest that anti-cruzipain immune responses could serve as potential biomarkers for Chagas disease progression and cardiac involvement.
Abstract:
The humoral immune response to epitopes expressed on cruzipain was evaluated in 31 Chagas disease patients (CDP) with different degrees of cardiac dysfunction. We took advantage of the availability of anti-Trypanosoma cruzi microsomal fraction monoclonal antibodies (MoAbs) reactive with epitopes that are recognized (5A9B11) or not recognized (1A10C11) by CDP sera. The 5A9B11- and 1A10C11-like epitopes are expressed on cruzipain. The reactivity of 5A9B11 against cruzipain was completely inhibited by sera of severe cardiopathy patients while a partial inhibition was found with sera from chagasic patients with mild disease. CDP sera did not block cruzipain recognition by 1A10C11. The antigenic determinants recognized by CDP sera appeared to be linear and carbohydrate free. When the overall anti-cruzipain immune response was evaluated, 70% of CDP with severe disease showed cruzipain titers higher than 1/800 while none of them displayed titers lower that 1/400. This report shows for the first time that the humoral immune response against epitopes expressed on cruzipain appeared to be related with the severity of chronic Chagas disease.